Corbus Pharmaceuticals, based in Norwood, Massachusetts, focuses on developing therapies for rare inflammatory diseases and cancer, with a pipeline including CRB-701 and CRB-601. The company went public on October 24, 2014, and employs 19 staff.
CRBP has been in the news recently: FedEx shares fell by over 13% due to a quarterly earnings decline and a lowered revenue forecast, attributed to reduced industrial demand and a shift to lower-cost delivery options. Additionally, Novo Nordisk A/S's report of a 7.1 kg weight loss with monlunabant led to significant stock declines for Corbus Pharmaceuticals and Skye Bioscience, dropping by 59.4% and 41%, respectively.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
